TrialCurveOE05: reconstructed Kaplan–Meier curves
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2017 Sep;18(9):1249–60. doi: 10.1016/S1470-2045(17)30447-3 |
|---|---|
| DOI | 10.1016/S1470-2045(17)30447-3 |
| Registry | NCT00041262 |
| Phase | Phase 3 |
| Conditions | Esophageal Cancer |
| Interventions | cisplatin, epirubicin hydrochloride, fluorouracil, conventional surgery, neoadjuvant therapy |
| Sponsor | Medical Research Council |
| Enrolment | 1300 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: ECX 2.2 years; CF 2.0 years. Survival at 2 years: ECX 53%; CF 51%. Hazard ratio ECX vs CF 0.90 (95% CI 0.77–1.05).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| ECX | 446 | 302 | 2.2 |
| CF | 451 | 328 | 2.0 |
- ECX vs CF: reconstructed HR 0.90 (95% CI 0.77–1.05)
Landmark survival (reconstructed)
| Time | ECX | CF |
|---|---|---|
| 1 yr | 77.9% | 77.0% |
| 2 yr | 52.8% | 50.6% |
| 3 yr | 42.2% | 39.3% |
| 5 yr | 31.7% | 29.3% |
| 7 yr | 30.2% | 25.0% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/oe05-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/oe05-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. 2017 Sep;18(9):1249–60. doi: 10.1016/S1470-2045(17)30447-3 doi:10.1016/S1470-2045(17)30447-3. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/oe05
Report a problem with these data
Related trials
- STARGATE: Overall survival; Progression-free survival (blinded central radiologic review)
- NEOCRTEC5010: Disease-free survival; Overall survival
- ROCS: Dysphagia deterioration-free survival (DDFS); Overall survival
- GLOW: Overall survival; Progression-free survival; Progression-free survival (investigator-asses
- Neoadjuvant chemoradiotherapy vs adjuvant therapy in ESCC: Disease-free survival; Overall survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials